Important: New Login Process

We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.

  • If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
  • If you log in with a username and password, you will be prompted to set a new password before accessing your account.

Go to the Login Page to get started.

We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.

BioCentury
ARTICLE | Company News

Lilly backs Topas' liver-specific nanoparticles platform

September 1, 2017 6:02 PM UTC

Topas Therapeutics GmbH (Hamburg, Germany) partnered with Eli Lilly and Co. (NYSE:LLY) to develop therapeutics that induce antigen-specific immune tolerance. The companies will initially focus on undisclosed external antigens thought to be involved in autoimmune and inflammatory diseases.

The partners will harness Topas' platform which uses peptide-loaded nanoparticles to selectively target liver sinusoidal endothelial cells (LSECs)...

Get Unlimited Access
Continue reading with a free trial.
Or Purchase This Article